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Abstract In Huntington's disease and other polyglutamine
(polyQ) disorders, mutant proteins containing a long polyQ
stretch are well documented as the trigger of numerous
aberrant cellular processes that primarily lead to degenera-
tion and, ultimately, the death of neuronal cells. However,
mutant transcripts containing expanded CAG repeats may
also be toxic and contribute to cellular dysfunction. The
exact nature and importance of RNA toxicity in polyQ
diseases are only beginning to be recognized, and the first
insights have mainly resulted from studies using simple
model systems. In this review, we briefly present the basic
mechanisms of protein toxicity in polyQ disorders and RNA
toxicity in myotonic dystrophy type 1 and discuss recent
results suggesting that the pathogenesis of polyQ diseases
may also be mediated by mutant transcripts. This review is
focused on the experimental systems used thus far to dem-
onstrate RNA toxicity in polyQ disorders and the design of
new systems that will be more relevant to the human disease
situation and capable of separating RNA toxicity from pro-
tein toxicity.
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Introduction
Nine human hereditary neurodegenerative disorders, includ-
ing Huntington's disease (HD) and several spinocerebellar
ataxias (SCAs), are caused by the abnormal expansion of
CAG repeats located in the translated sequences of different
genes [1] (Fig. 1). For example, HD is triggered by the
expression of at least 36 CAG repeats located in exon 1 of
the HTT gene, which encodes the large and multifunctional
huntingtin protein (Htt) [2]. SCA1 is caused by at least 39
CAG repeats present in exon 8 of the ATXN1 gene, which
codes for the ataxin-1 protein involved in RNA metabolism
and transcriptional regulation [3], and SCA3 (also known as
Machado–Joseph disease) is induced by at least 60 CAG
repeats that occur in exon 10 of the ATXN3 gene encoding a
protein with deubiquitinating activity [4]. The CAG repeats
are translated into polyglutamine tracts in protein products,
and the entire group of resulting disorders is known as the
polyglutamine (polyQ) diseases. Each polyQ disorder pri-
marily affects a different population of neurons, although
the causative genes are widely expressed in the central
nervous system and peripheral tissues. The expanded
repeats are thought to exert their pathogenic effects at the
protein level, mainly through a gain of toxic function by the
mutant protein [1]. For comparison, myotonic dystrophy
type 1 (DM1), which is another example of a triplet repeat
expansion disease (TRED), is caused by 50–3,000 copies of
CTG tandem repeats located in the 3′ untranslated se-
quence of the dystrophia myotonica protein kinase gene
(DMPK) [5]. In DM1, the gain of toxic function by
mutant transcript containing CUG repeats is proposed
to explain its pathogenesis [6, 7].
The pathogenic number of CAG repeats in genes impli-
cated in polyQ diseases is, in most cases, lower than the
number of CUG repeats in the DMPK gene of DM1
patients, and CAG expansions typically span a much nar-
rower range of repeat lengths (Fig. 1). Nevertheless, a con-
siderable fraction of HD and SCA patients harbor mutant
CAG repeats of a length corresponding to the lower range of
CUG repeat lengths found in DM1. The expression levels of
individual polyQ disease genes and the DMPK gene differ
within and between tissues; however, they all belong to the
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moderate or low expression category [8, 9]. The structural
features of the CAG repeats are similar to the CUG repeats,
forming hairpin structures in transcripts when the repeat
tracts are long enough [10–16]. The repeats of normal length
form small and semistable hairpins, and mutant repeats form
long hairpins that are more stable [17]. According to the
results of crystallographic studies, the CAG repeat duplexes
and CUG repeat duplexes show a high degree of similarity
[18, 19], suggesting that the stem portion of these hairpins
may share some protein-binding properties [20, 21].
In this review, we first discuss the main cellular and
molecular hallmarks of the mutant protein and mutant
RNA gain-of-function mechanisms from studies of polyQ
diseases and DM1 pathogenesis. We then present recent
findings indicating that transcripts containing expanded
CAG repeats might also be toxic and contribute to the
pathogenesis of polyQ disorders. Finally, we focus on the
experimental models used to demonstrate RNA toxicity in
polyQ diseases. We discuss the features of these models and
propose generating new cellular and animal models dedicat-
ed to elucidating the toxic effects triggered by mutant RNA
and protein in polyQ diseases.
Mechanisms of protein toxicity in polyQ diseases
and RNA toxicity in DM1
PolyQ toxicity
The protein products of genes that undergo mutations leading
to polyQ diseases differ in their cellular functions and cover a
wide range of molecular weights [1]. A common feature of
these proteins is the presence of a polyQ tract that is expanded
as the result of the mutation. However, the exact nature of
protein gain-of-function toxicity in polyQ diseases remains a
subject of debate [22, 23], and two mechanisms have been
considered: the gain of a new toxic function by the mutant
protein and the enhancement of the normal protein function to
toxic levels. In either case, the key to understanding the details
of such pathogenic mechanisms is the identification and char-
acterization of new toxic protein–protein interactions and
imbalanced normal interactions. A systematic search for pro-
teins associated with normal and expanded Htt has recently
been performed using quantitative proteomic analysis [24].
The data showed that the proteins that preferentially interacted
with mutant Htt are enriched for intrinsically disordered pro-
teins and proteins involved in key cellular functions, such as
energy production, protein trafficking, RNAmodification and
translation, mitochondrial functions, cellular stress, and cell
death. These results confirmed and expanded earlier findings
regarding the cellular processes and pathways that are altered
in HD [25–27].
The pathogenesis of polyQ diseases is believed to be
initiated by the expanded polyQ tract, which is thought to
acquire a β-sheet conformation and cause the mutant protein
to misfold [28]. Alternatively, the expanded polyQ stretch
may stabilize one of several conformations characteristic of
the wild-type protein that may normally exist in equilibrium
[22]; such an effect enhances some intermolecular interactions
of the mutant protein at the cost of other interactions. In
addition to the polyQ tract, the context of other protein
domains may also contribute to pathogenesis, as demonstrated
Fig. 1 Comparison of the lengths of the CAG repeat tracts that occur
in polyQ disease-related transcripts and the CUG repeats in the tran-
script responsible for DM1. The normal repeat range is marked in
green, and the mutant repeat range is marked in red and specified.
The repeat range marked in gray refers to unidentified or undefined
tracts. The starting threshold for DM1 mutation (50 repeats) is denoted
by a hatched line
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in animal models of spinal–bulbar muscular atrophy [29],
SCA1 [30], and HD [31]. In several instances (reviewed in
[32–34]), single amino acid substitutions in functional
domains of relevant proteins resulted in dramatic changes of
disease phenotypes pointing to the critical role of protein
toxicity in polyQ diseases.
The cellular hallmarks of polyQ diseases are nuclear and
cytoplasmic amyloid-like aggregates formed by mutant pro-
teins, their proteolytic fragments [35, 36], or by fragments
translated from aberrantly spliced shorter mRNAs [37] that
sequester other proteins, predominantly those containing
unstructured regions [24, 28, 38]. The formation of
amyloid-like deposits is also observed in Parkinson and
Alzheimer diseases, with which the protein toxicity of
polyQ diseases is often compared. However, in efforts
aimed at demonstrating RNA toxicity in polyQ diseases,
reference to DM1 and other RNA-triggered TREDs, e.g.,
SCA8 [39] and HDL2 (Huntington's disease-like 2) [40,
41], is both appropriate and justified [20, 21, 42–44].
CUG repeat toxicity
DM1 is the prototype of TREDs caused by toxic RNA [6, 7].
Terms such as “toxic RNA” and “RNA toxicity” are used to
reflect the fact that the disease-causing mutation is passed
from the gene to the transcript only, while the protein structure
is unaffected by the mutation. The hallmarks of cells express-
ing expanded CUG repeats are nuclear RNA foci [45], which
are toxic to cells because they sequester important cellular
proteins, reducing their normal, functional levels (reviewed in
[46, 47]). One such protein trapped in mutant RNA foci is
muscleblind-like (MBNL1) alternative splicing factor [48];
together with the concomitant upregulation of the antagonistic
splicing factor CUG-BP1 [49], MBNL1 deficiency results in
the misregulation of the developmentally regulated alternative
splicing of numerous MBNL1-regulated genes. The compro-
mised functions of some of these genes have been linked to
the clinical symptoms of DM1, e.g., the altered splicing of
insulin receptor in insulin resistance [50], chloride channel 1
in myotonia [51], sarcoplasmic/endoplasmic reticulum Ca2+
ATPase 1 and 2 in muscle wasting [52], cardiac troponin T in
cardiac abnormalities [53], and Tau (MAPT) in cognitive
deficits [54]. The binding of the multifunctional helicases
p68 and p72 to mutant CUG repeats facilitates the binding
of MBNL1 to the repeats [55] and likely links the DM1
pathogenesis pathway to the nuclear step of microRNA bio-
genesis, a process in which these helicases are involved as
cofactors of the ribonuclease Drosha complex [56]. Direct
evidence was provided for the crosstalk between the DM1
pathogenesis pathway and the cytoplasmic ribonuclease Dicer
step of microRNA biogenesis, in which theMBNL1 protein is
also implicated [57]. It was demonstrated that MBNL1 se-
questered by mutant CUG repeats cannot effectively function
in its newly recognized role as a pre-miRNA cleavage regu-
lator, resulting in the compromised expression and function of
some miRNAs, including miR-1, an effect linked to DM1-
related heart defects. The expanded CUG repeats were also
shown to trigger immune responses in DM1 tissue in which
the PKR, OAS, TLR3, and RIG I genes were activated [58].
Accumulating evidence for RNA toxicity in polyQ
diseases
Although the contribution of RNA toxicity to the pathogen-
esis of polyQ diseases was previously postulated based on
the structural similarities between the CAG and CUG
repeats in transcripts [10, 17], the first compelling experi-
mental evidence for such an involvement was provided in
2008 by Bonini and colleagues [59]. Using a Drosophila
melanogaster model system, the researchers demonstrated
that the expression of both translated and untranslated RNA
molecules containing long hairpin-forming CAG repeat
tracts causes neurodegeneration, whereas the expression of
RNA containing CAA-interrupted CAG repeats resulted in
considerably less pronounced neurodegenerative features.
CAA triplets also encode glutamine but are unable to form
a hairpin structure [11], and their occurrence within CAG
repeat tracts [60, 61] destabilizes CAG repeat hairpins [15].
Other studies that were performed in nonhuman model
systems provided further evidence for the toxicity of CAG
repeats. Hsiao and colleagues showed that in transgenic
Caenorhabditis elegans, similar to CUG repeats, CAG
repeats of toxic length formed nuclear foci that colocalized
with CeMbl, which is the worm homolog of MBNL1 [62].
Worms expressing the toxic CAG repeats showed shortened
lifespan and reduced motility rates, which is consistent with
the phenotypes of worms expressing toxic CUG repeats. As
shown by Pan and colleagues, the expression of 200 CAG
repeats from the 3′UTR of EGFP was toxic in transgenic
mouse muscle and testis tissues in which the expression of
the transgene was directed [63]. Importantly, ribonuclear
foci and abnormal phenotypes were observed in the absence
of a polyQ product expression.
The formation of CAG repeat RNA foci that colocalize
with MBNL1 protein was, for the first time, demonstrated
by Cooper and colleagues through the expression of very
long exogenous CAG repeats in monkey COSM6 cells [64].
A question that was addressed using human cell lines was
whether less CAG repeats could also form nuclear foci and
cause alternative splicing aberrations similar to those known
for DM1. The results showed that these effects are triggered
in both HeLa and neuroblastoma SK-N-MC cells transiently
expressing mutant CAG repeats [65]. In addition, we dem-
onstrated that the expanded CAG repeats present in HTT
and ATXN3 transcripts also occur within intranuclear
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MBNL1-positive RNA foci in human HD and SCA3 fibro-
blasts. Although the focus formation was accompanied by
the aberrant alternative splicing of several endogenous
MBNL1-dependent transcripts, this only occurred in cells
expressing approximately 70 CAG repeats and not a lower
number of approximately 45 CAGs [65]. Very recently,
Bates and colleagues have demonstrated the CAG repeat
length-dependent aberrant splicing of the HTT exon 1 giving
rise to short polyadenylated exon 1-intron 1 mRNAwhich is
translated to the toxic HTT exon 1 protein [37]. The aberrant
splicing is triggered by the increased binding of the alternative
splicing factor SRSF6 to expanded CAG repeats. Thus, it is
likely that the pathogenesis of polyQ disorders involves, at
least to some extent, the primary elements of the RNA gain-
of-function mechanism that is well characterized in DM1.
Consistent with the above nuclear effects, a protein that is
responsible for the nuclear export of transcripts harboring
expanded CAG repeats has been identified by Chan and
colleagues as the small nuclear RNA U2-associated factor
U2AF65 [66]. This factor binds directly to expanded CAG
repeats and forms a complex with the nuclear export receptor
NXF1 and its reduction in symptomatic tissues is linked to
accumulation of mutant RNA in the nucleus.
An RNAi mechanism has been shown to be involved in
pathogenesis in several in vivo and cellular models of polyQ
diseases. As demonstrated by Bonini and colleagues [67]
and Richards and colleagues [44] in two independent stud-
ies, the co-expression of exogenous expanded CAG and
CUG repeats in fly cells resulted in a neurodegenerative
phenotype. The complementary repeats likely formed a
double-stranded RNA that was cleaved by Dicer-2 into 21
nt CAG/CUG repeat siRNAs, which were active in silencing
in an Ago2-dependent process. Margolis and colleagues
[68] discovered a natural antisense transcript, HTTAS, at
the HD repeat locus that contains the CUG repeat tract. This
transcript was shown to regulate sense HTT transcript ex-
pression in a process dependent on the repeat length and
partly dependent on Dicer and the RISC pathway. The
involvement of an RNAi mechanism was also demonstrated
by Marti and colleagues in human cell lines expressing
mutant CAG repeats flanked by the HTT exon 1 sequence
[69]. The mutant CAG repeats, both translated and untrans-
lated, gave rise to a toxic small RNA species (sCAG) in a
Dicer-dependent manner and caused a downstream silenc-
ing effect in an Ago2-dependent manner. Again, the cyto-
toxic effects were triggered only by CAG repeats and not by
CAA repeats. The involvement of the miRNA biogenesis
pathway in the pathogenesis of polyQ diseases is only
circumstantial, based on the ability of the MBNL1 [16, 64,
65] and p68 [55] proteins to bind to both CUG repeats and,
though less efficiently, CAG repeats.
The recent study by Chan and colleagues revealed that
CAG repeat expansion induces nucleolar stress in polyglut-
amine diseases [70], demonstrating that the expanded CAG
repeat RNA interacts directly with nucleolin and that this
interaction triggers a number of aberrant downstream cellu-
lar processes, eventually leading to cell apoptosis. These
downstream effects include hypermethylation of the up-
stream control element of the rRNA promoter and the inhi-
bition of rRNA transcription. The reduced level of rRNA
results in the accumulation of free ribosomal proteins, and
the interaction of these proteins with MDM2 E3 ubiquitin
ligase causes mitochondrial p53 accumulation. The interac-
tion between p53 and the antiapoptotic protein Bcl-xL
causes the oligomerization of the proapoptotic protein Bak
at the mitochondrial membrane and allows for cytochrome c
release to the cytosol, an event that activates the caspase
cascade and induces apoptosis [70]. Collectively, several
mechanisms of RNA toxicity have been revealed that may
likely participate in the pathogenesis of polyQ diseases;
however, the entire scale of toxic RNA contribution to the
disorders and the range of cellular processes and pathways
altered by mutant transcripts remain unknown.
Experimental models used to trace RNA toxicity
in polyQ diseases
Various genetic models have been used to demonstrate the
first examples of CAG repeat RNA toxicity described in the
previous section. The characteristics of these model systems
and the main results obtained from their application are com-
piled in Table 1. It is apparent that this type of RNA toxicity
has thus far been modeled in lower invertebrates, nematode
worms, and fruit flies in addition to mammalian systems,
including mice and monkey and human cell lines. However,
a common issue in modeling human diseases in lower organ-
isms is the relevance of the results obtained with simpler
model systems of human disease. Indeed, relevance is hard
to prove by merely a sufficient similarity of the genetic path-
ways operating in model organisms and humans. For polyQ
diseases and TREDs in general, this task is more difficult, as
these late-onset diseases only occur naturally in humans and
not in shorter living animals in which the experimental induc-
tion of similar effects requires stronger triggers, i.e., longer
repeat tracts and in some cases higher expression levels. In
most studies, the expression of transgene was determined but
the level not referred to the expression of endogene (homo-
logue of human polyQ gene) or any other gene. Most authors
related the expression of a single construct to the expression of
other transgene variants. In case of mouse models R6/2,
BACHD, and YAC128, the expression level of transgene
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Table 1 Characteristics of model systems used for the investigation of
RNA-mediated toxicity caused by expanded CAG repeats. The table is
organized according to the species of model organism and includes
human cell lines. Only mutant repeat tracts used in the studies are
listed. Constructs containing untranslated repeat tracts are underlined.
Note that some constructs contained either pure CAG or CAA repeats,
and some contained other CAA-interrupted CAG repeats. The CAG
repeats interrupted with CAA or pure CAA tracts are presented in bold
Construct characteristics Main conclusions Reference
Repeat tract Sequence context Promoter/expression
Caenorhabditis elegans
(CAG) 83 GFP 3′UTR myo-3 (muscle) •CAG repeats, similar to CUG repeats, are toxic






(CAG) 52, 99 MYC FLAG gmr-GAL4 (eye) •The expression of expanded and translated




(CAG) 93 3′UTR •Untranslated CAG repeats do not induce
pathology
SCA3trQ78(CAG) ATXN3 truncated gmr-GAL4 (eye) or elav-GAL4
(neurons)




SCA3nQ84(CAG) ATXN3 full length •Long, untranslated CAA-interrupted CAG
repeats are not toxicSCA3nQ81(CAA/G)
(CAG) 100 or 250 DsRed2 3′UTR
(CAA/G) 105 or 262
(CTG) 250 DsRed2 3′UTR gmr-GAL4 (eye), 24B-GAL4
(muscle), or hs-GAL4
(ubiquitous by heat-shock)
•Simultaneously expressed expanded CAG









•The expression of CAG and CUG repeats
leads to RNAi-dependent neurodegeneration
[44]
rCTG ∼ 100
SCA3trQ78(CAG) ATXN3 truncated gmr-GAL4 (eye) •The NXF1/U2AF65-mediated RNA export




•The interaction of CAG repeats with nucleolin
triggers numerous downstream toxic effects
[70]
(CAG) 100 or 250 DsRed2 3′UTR elav-GAL4 (neurons) •The CAG100-expressing flies show aberrant
expression of numerous brain genes
[79]
(CAA/G) 105




•The expression of CUG or CAG (but not
CAA) repeat-containing transcripts causes
morphological defects
[80]
4x rCTG ∼ 100
4x rCAA ∼ 100
Mus musculus
(CAG) 44 HTT cDNA
full-length
CMV (ubiquitous)/construct
described to be highly
expressed in particular
transgenic line
•No observed neuropathological changes or
behavioral abnormalities in 1-year-old mice
overexpressing mutant HTT transcript
[73]
(CAG) 200 EGFP 3′UTR gsg (skeletal muscle) •Transgenic mice expressing EGFP transcripts
with long CAG repeats in the 3′UTR develop
pathogenic features
[63]
R6/2 HD mice HTT exon 1 HTT promoter (ubiquitous)/
average tissue expression:
75 % relative to endogene [71]
•NXF1/U2AF65 RNA export pathway associates
with expanded CAG RNA-mediated toxicity
[66]
(CAG)115-150 •Expanded repeat CAG RNAs interact with
nucleolin and trigger nucleolar stress and
induce apoptosis via the p53 pathway
[70]
BACHD – 97Q (48
CAG, 49 CAA)a
YAC128 – 125Q
(116 CAG, 9 CAA)
HTT full length HTT promoter (ubiquitous)/
expression in brain close to
endogenous Htt
•Distinct CAA interruption patterns may be
implicated in the observed phenotypic
differences in two HD models
[72]
Mammalian cultured cells
(CTG) 960b DMPK exons 11–15 CMV COSM6 monkey cells /
expression higher than
endogenous
•mRNAs containing CAG repeats form nuclear
RNA foci that colocalize with MBNL1
[64]
(CAG) 960c
(CAG) 74 EGFP 3′UTR fusion
construct EGFP-
mutATXN3 (69 CAG)
CMV, HeLa, and SK-N-MC
human cell lines/expression
higher than endogenous
•Exogenous transcripts expressing long
untranslated CUG or CAG repeats trigger





40 CAG HTT exon 1 HMEC, HPDE, HeLa, and
SH-SY5Y human cell lines
•The expression of expanded HTT exon-1
transcript with CAG repeats gives rise to small
CAG-repeated RNAs generated by





a The repeated pattern was CAG CAG CAA CAG CAA CAA
b Every 20 repeats were interrupted with CTCGA
c Every 20 repeats were interrupted with TCGAG
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did not differ much from that of homologous endogene [71,
72]. In case of constructs tested in mammalian systems, con-
taining CMV promoters, the expression level of transgene was
reported as very high [64, 65, 73]. The worm and fly systems
satisfactorily fulfilled the requirement of genetic similarity,
and both systems were capable of demonstrating some mo-
lecular and phenotypic hallmarks of RNA toxicity. Although
more relevant and potentially more informative than the fly
systems, transgenic mouse models have less frequently been
used, and human cellular models have been used for this
purpose only twice.
The genetic systems shown in Table 1 differ considerably
with regard to their molecular design. Most models are
transgenic and express exogenous expanded repeats that
have the potential to trigger pathogenesis by a variety of
mechanisms involving aberrant interactions with host pro-
teins. Of importance in these systems is the intragenic lo-
calization of repeated sequences. In some experimental
systems, the repeats are located within the open reading
frame (ORF) and are typically transcribed and translated;
the expressed mutant repeats are present within the sequence
context of either the full-length human disease transcript or
only a fragment of this transcript. Alternatively, the repeats
are placed within the 3′UTR sequence of a heterologous
gene and are only transcribed. The genes hosting mutant
repeats are usually a marker gene, such as GFP or DsRed. In
addition, the length and purity of the CAG repeat tracts are
important factors in the design of a model system; the
repeated sequence typically falls into the upper range of
repeat lengths found in human subjects suffering from the
disease and is often modified to contain CAA repeats.
The ideal model of a polyQ disease would be one that
closely recapitulates the human disease with regard to most
of its aspects [36]. Thus, human cell lines are well suited to
study the details of the molecular mechanisms that are
implicated in triggering pathogenesis. The rapid develop-
ment of induced pluripotent stem (iPS) cell technology
enables somatic cells to be transformed into iPS cells and
then differentiated to neuronal cell lines [74]. Moreover, the
advent of gene-editing technologies has begun to enable the
precise engineering of human disease-related endogens [75].
Both technologies may provide highly informative cellular
models for future studies. The expression of mutant exoge-
nous full-length cDNA using the well-established technolo-
gies of transgenesis may also be considered as an option for
the construction of in vitro models of polyQ diseases. A
good transgenic mouse model of polyQ disease should
express the CAG repeat mutation within the sequence con-
text of the entire human gene, with sufficient upstream and
downstream regulatory sequences to ensure the proper spa-
tial and temporal expression of the human gene at natural
levels [72, 76]. In general, model systems expressing a full-
length human mRNA, despite showing milder disease
phenotypes, are better suited for studies aimed at discover-
ing new mechanisms of RNA toxicity than systems express-
ing only shorter or longer mRNA fragments. In the full-
length RNA models, the mutant transcript has a chance to go
through all steps of mRNA cellular journey from its “birth”
in the nucleus to “death” in the cytoplasm; therefore, all
steps altered by the mutation may be identified.
A serious difficulty in identifying the involvement of
RNA toxicity in polyQ diseases is the overlap with the
polyQ toxicity in models expressing CAG repeats from the
ORF, and placing the repeat in the untranslated sequence of
a heterologous gene is frequently used to overcome this
difficulty and trace the effects of mutant RNA. However,
preventing transcript translation by the mutation of the
START codon in a polyQ disease gene or its cDNA resolves
this problem while preserving the natural sequence context
and expression level for the repeats. Based on the assump-
tion that the non-AUG-initiated translation of repeated
sequences [77] is not a very common phenomenon, the
START codon mutation may indeed be considered a better
solution. By mutating the START codon also in constructs
expressing CAA repeats or CAA-interrupted CAG repeats,
the four model types depicted in Fig. 2 may be generated.
With these in vitro and in vivo models critical experiments
using both transcriptome-wide and more focused candidate
approaches have to be done to obtain clear-cut answers
regarding the role of mutant transcripts in the pathogenesis
of polyQ diseases.
Fig. 2 Four types of models that can be used to separate RNA toxicity
and protein toxicity in the investigation of the pathogenesis of CAG
repeat diseases. The depicted models express one of two types of
repeated sequences, either CAG or CAA. Both sequences code for
glutamine, but only the CAG repeat forms a hairpin structure in tran-
scripts. In these types of models, both repeats are expressed in their
translated or untranslated forms, depending on the absence or presence
of an AUG START codon mutation. Potentially toxic entities, an
expanded CAG repeat-containing transcript and a polyQ-containing
protein, are marked in red; a transcript containing expanded CAA
repeats, presumed to be nontoxic, is marked in blue
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Concluding remarks
Research on RNA toxicity in polyQ diseases is still in its
infancy. At this stage, there is a marked disproportion between
the ability of a model organism to closely reproduce human
disease and the frequency with which the model system has
been used in the search for RNA toxicity hallmarks.
Nevertheless, most of the genetic models provided in Table 1
have succeeded in demonstrating the first examples of RNA
toxicity caused by expandedCAG repeats. Future studies along
this line will require the more extensive use of dedicated mouse
models and the next generation of human cellular models.
The studies performed thus far have revealed the involve-
ment of several cellular processes and pathways in CAG
repeat RNA toxicity. These altered processes include aberrant
alternative splicing, transcript nuclear transport and export,
RNA interference, and nucleolar stress resulting in apoptosis.
All these processes are triggered by aberrant interactions
between cellular proteins and mutant RNA. The proteins that
participate in direct or indirect interactions with mutant CAG
repeat transcripts need to be identified in further studies, and
their role in pathogenesis needs to be elucidated. Such efforts
may help to determine the contribution of RNA toxicity to the
overall toxicity caused by both toxic factors: the protein and
the RNA. This endeavor may also provide the basis to answer
the question of whether the RNA and protein toxicities inter-
act with each other to enhance pathogenesis or whether these
toxic processes are parallel and independent. Another issue to
be clarified is whether the RNA and protein toxicities require
the same or different repeat length thresholds to become
operative. The latter alternative may likely be the case, and a
higher number of repeats may be required to initiate the RNA-
mediated toxic processes.
Finally, depending on the scale and repeat length thresh-
olds for the various pathogenic mechanisms triggered by
mutant RNA, these factors may impact the causative thera-
peutic approaches to combat polyQ diseases to a higher or
lower extent. Should RNA toxicity be proven to contribute
significantly to disease development and progression, both
the inhibition of mutant protein synthesis and the blockage
or degradation of mutant transcript will be required.
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